IP Library Granted Patent US 11,266,693
Granted Patent B2
US 11,266,693 · App. 17/016,056 · Granted Mar 8, 2022

Nucleic acids encoding engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene

Inventors: Michael G. Nicholson (Chapel Hill, NC); James Jefferson Smith (Morrisville, NC); Derek Jantz (Durham, NC); Victor Bartsevich (Durham, NC); Daniel T. MacLeod (Durham, NC); Jeyaraj Antony (Chapel Hill, NC)
Assignee: Precision BioSciences, Inc.
A61K35/17A61K47/42A61K47/65A61K47/67A61P35/00C12N9/22A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,266,693
App. No.
17/016,056
Granted
Mar 8, 2022
Kind
B2
Abstract

Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene. The present disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells.

Claims (9)

1. An isolated polynucleotide comprising a nucleic acid sequence encoding an engineered meganuclease, wherein said engineered meganuclease binds and cleaves at a recognition sequence consisting of SEQ ID NO: 3, wherein said engineered meganuclease comprises a first subunit and a second subunit, wherein said first subunit binds to a first recognition half-site of said recognition sequence, and wherein said second subunit binds to a second recognition half-site of said recognition sequence, and wherein said engineered meganuclease comprises an amino acid sequence having at least 96% identity to SEQ ID NO: 8.

2. The isolated polynucleotide of claim 1 , wherein said first subunit comprises an amino acid sequence having at least 96% sequence identity to residues 198-344 of SEQ ID NO:8, and wherein said second subunit comprises an amino acid sequence having at least 96% sequence identity to residues 7-153 of SEQ ID NO: 8.

3. The isolated polynucleotide of claim 1 , wherein said first subunit comprises residues 198-344 of SEQ ID NO: 8.

4. The isolated polynucleotide of claim 1 , wherein said second subunit comprises residues 7-153 of SEQ ID NO: 8.

5. The isolated polynucleotide of claim 1 , wherein said engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 8.

6. The isolated polynucleotide of claim 1 , wherein said isolated polynucleotide is an mRNA.

7. A recombinant DNA construct comprising said isolated polynucleotide of claim 1 .

8. A viral vector comprising said isolated polynucleotide of claim 1 .

9. The viral vector of claim 8 , wherein said viral vector is a recombinant adeno-associated virus vector.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2020
From: NICHOLSON, MICHAEL G.; SMITH, JAMES JEFFERSON; JANTZ, DEREK; BARTSEVICH, VICTOR; MACLEOD, DANIEL T.; ANTONY, JEYARAJ
To: PRECISION BIOSCIENCES, INC.
Reel/Frame 054717/0882 →
Continuity (4)
Division 15766290
Provisional Application 62297445 · Feb 19, 2016
Provisional Application 62237382 · Oct 5, 2015
Related Publication 20210052650A1 · Feb 25, 2021